Prestige Consumer Healthcare Stock Forecast, Price & News

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PBH stock has increased by 9.4% and is now trading at $39.27.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Prestige Consumer Healthcare stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBH, but not buy additional shares or sell existing shares.
View analyst ratings for Prestige Consumer Healthcare or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Prestige Consumer Healthcare a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prestige Consumer Healthcare wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

8 employees have rated Prestige Consumer Healthcare CEO Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among Prestige Consumer Healthcare's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Prestige Consumer Healthcare.

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its earnings results on Thursday, November, 5th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.06. The firm had revenue of $237.42 million for the quarter, compared to analyst estimates of $227.43 million. Prestige Consumer Healthcare had a net margin of 17.03% and a trailing twelve-month return on equity of 13.76%. The firm's revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS.
View Prestige Consumer Healthcare's earnings history.

Prestige Consumer Healthcare updated its FY22 earnings guidance on Thursday, November, 5th. The company provided earnings per share guidance of approx $3.18 for the period, compared to the Thomson Reuters consensus estimate of $3.25.

7 brokers have issued twelve-month price targets for Prestige Consumer Healthcare's stock. Their forecasts range from $39.00 to $125.00. On average, they anticipate Prestige Consumer Healthcare's stock price to reach $80.17 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare or view Wall Street analyst' top-rated stocks.

Some companies that are related to Prestige Consumer Healthcare include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), Inter Parfums (IPAR), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of PBH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Prestige Consumer Healthcare's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.50%), Peregrine Capital Management LLC (0.47%), Dalton Greiner Hartman Maher & Co. (0.24%), Nisa Investment Advisors LLC (0.05%), Diversified Trust Co (0.03%) and OLD National Bancorp IN (0.02%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare.

PBH stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Wedge Capital Management L L P NC, Pacer Advisors Inc., Diversified Trust Co, OLD National Bancorp IN, Janney Montgomery Scott LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Prestige Consumer Healthcare or view top insider-selling stocks.

PBH stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, XTX Markets LLC, Nisa Investment Advisors LLC, and Exchange Traded Concepts LLC.
View insider buying and selling activity for Prestige Consumer Healthcare or or view top insider-buying stocks.

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PBH stock can currently be purchased for approximately $39.27.

Prestige Consumer Healthcare has a market capitalization of $1.97 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 520 workers across the globe.

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]